Patient's Whole Process Follow-up Management(HOPE-1)
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- В протоколе указаны: Patients' whole process follow-up and management platform.
- Кому может быть актуально
- Состояния в реестре: Locally Advanced Non-Small Cell Lung Cancer, Metastatic NSCLC. Базовые параметры: от 18 лет · Все.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- Китай
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Официальное название
A Multicenter, Randomized, Open, Parallel Grouping, Investigator-initiated Study Evaluating the Long-term Benefit of Patients With Locally Advanced/Metastatic Non-small Cell Lung Cancer Followed up Using a Patient-wide Management Platform
Обзор
Our project is going to explore whether management and follow-up of locally advanced/metastatic patients using the patient process management platform can prolong patient survival and improve patient quality of life.
Подробное описание
Now, the treatment of NSCLC is diversiform, such as radiation and chemotherapy, targeted therapy, immune therapy, the treatment goal is to reduce symptoms, improve quality of life, prolong life. But as a result of the disease itself has the high risk of metastasis and recurrence. The treatment is often accompanied by a series of complications, if the patients don't get medical assistance in time, it will lead high risk to physical and mental health of patients. In China, the intermittent period of domestic treatment is mainly family recuperation, but due to the lack of medical knowledge or self-management and self-restraint ability of patients, they may forget to take medicine, stop medication without permission due to side effects and other behaviors that do not follow the doctor's advice, the poorly patients' compliance will lead to a significant reduction in the treatment effect. NSCLC are often accompanied by anxiety, fear, insomnia and other symptoms, causing a huge psychological burden on patients and their families, affecting the quality of life. Whole process follow-up in tumor therapy plays an important role , it is the crucial link between medical, nursing, and patients. Patients' whole process follow-up and management is an important part of cancer disease management.
It is helpful to relieve the patients and their families of the bad psychology, reduce the symptoms of patients, improve the patient's compliance behavior, relieve the psychological anxiety of patients, make it actively cooperate with the treatment, reduce complications, improve the quality of life of patients, so as to prolong the life cycle.
Our project is going to explore whether management and follow-up of locally advanced/metastatic patients using the patient process management platform can prolong patient survival and improve patient quality of life.
Вмешательства
- Другое Patients' whole process follow-up and management platform
Patients' whole process follow-up and management platform is a software for the patients and investigators. This platform will use to collect patients' information when they are out of patients and will provide the patients' education materials.
Первичные конечные точки
- Overall survival time [Срок оценки: UP to 96 months]
Вторичные конечные точки (5)
- Progression-free survival (PFS) [Срок оценки: Up to 96 months]
- Adverse events rate [Срок оценки: Up to 96 months]
- Patients' follow-up compliance [Срок оценки: Up to 96 months]
- The quality of life [Срок оценки: Up to 96 months]
- Follow-up satisfaction [Срок оценки: Up to 96 months]
Критерии участия
Критерии включения
- Fully understand the research and voluntarily sign the informed consent form (ICF)
- Male or female subjects who are over 18 years old (inclusive) at the time of signing the informed consent form.
- The subject is diagnosed pathologically or cytologically with non-small cell lung cancer(NSCLC).
- According to the 8th edition of the American Joint Committee on Cancer \[AJCC\], it is classified as stage IIB, stage III, stage IV NSCLC.
- Not suitable for radical treatment or refuse surgery.
- The life expectancy is not less than 3 months.
- Be able to use a smartphone.
Критерии исключения
- Patients with mental illness.
- Presence of any other malignant tumor.
- Patients who are expected to undergo radical surgery.
- Currently participating in clinical trials.
- Subjects who judged by the investigator to be unsuitable to participate in the trial.
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Здоровые добровольцы: Нет
Дизайн исследования
- Модель наблюдения
- Когортное
Центры проведения
Китай · 1 центр
- The First Affiliated Hospital of Shandong First Medical University — Цзинань
Идентификаторы
NCT: NCT05339568 · WYKA001